Post-transplant Lymphoproliferative Disease (PTLD) (DBCOND0046848)

Identifiers

Synonyms
Posttransplant Lymphoproliferative Disorder / Post Transplant Lymphoproliferative Disorder / PTLD / Post-Transplant Lymphoproliferative Disorder / Post-Transplant Lymphoproliferative Disease / Post-transplant lymphoproliferative disorder (PTLD) / Post-transplantation Lymphoproliferative Disorder / Post-transplantation Lymphoproliferative Disorders / PTLDs / Post-transplantation lymphoproliferation (morphologic abnormality) / Lymphoproliferative disorder following transplantation (disorder)

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT00590447
Risk Stratified Sequential Treatment for CD20-positive PTLDtreatment2completed
NCT02042391
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapytreatment2completed
NCT05453396
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignanciestreatment2recruiting
NCT01748721
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphomatreatment1completed
NCT04507477
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trialprevention1 / 2unknown_status
NCT03386539
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Scoretreatment3active_not_recruiting
NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT01815749
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaNo drug interventionstreatment1active_not_recruiting
NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomastreatment1 / 2terminated
NCT01254578
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancerstreatment1completed
NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphomatreatment2completed
NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphomatreatment1completed
NCT01116154
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphomatreatment1terminated
NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapytreatment1completed
NCT00354185
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomatreatment1terminated
NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplanttreatment1 / 2completed
NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciestreatmentNot Availablecompleted
NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancertreatment1 / 2completed
NCT04337827
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disordertreatment2terminated
NCT02763254
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomastreatment2terminated
NCT02652715
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaNo drug interventionsbasic_scienceNot Availablecompleted
NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_care1completed
NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT01434472
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphomatreatment2terminated
NCT01261247
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphomatreatment2completed
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumorstreatment1completed
NCT01075321
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphomatreatment1 / 2completed
NCT00918333
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphomatreatment1 / 2completed
NCT00348985
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1completed
NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancertreatmentNot Availablecompleted
NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00064246
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disordertreatment1 / 2completed
NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancertreatment2completed
NCT00036855
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphomatreatment1terminated
NCT06040320
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)treatment1 / 2recruiting
NCT04189835
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant RecipientsNo drug interventionsNot AvailableNot Availablerecruiting
NCT03546101
Early Detection of Epstein-Barr Virus Related Disease.No drug interventionsNot AvailableNot Availablecompleted
NCT03086395
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)treatment2withdrawn
NCT02580539
A Study of the Safety and Efficacy of EBV Specific T-cell LinesNo drug interventionstreatment1 / 2recruiting
NCT02153580
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemiatreatment1active_not_recruiting
NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignanciessupportive_care2completed
NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignanciestreatment2withdrawn
NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignanciestreatment2completed
NCT01231919
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaNo drug interventionstreatment1completed
NCT01129180
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphomatreatment1completed
NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerNo drug interventionssupportive_careNot Availablecompleted
NCT00867529
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphomatreatment2completed
NCT01760226
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignanciestreatment0completed
NCT05688241
EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ DiseasesNo drug interventionstreatment1 / 2not_yet_recruiting
NCT01088724
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)treatment4completed
NCT04138875
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)treatment2withdrawn
NCT06422715
PTLD: Multicentric Retrospective StudyNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT05258136
Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBVNo drug interventionstreatmentNot Availableunknown_status
NCT02318030
CNTRP POSITIVE StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT03131934
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplanttreatment0active_not_recruiting
NCT01058239
Bortezomib Plus Rituximab for EBV+ PTLDtreatment2completed
NCT01964755
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphomatreatment2terminated
NCT01458548
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)treatment2terminated
NCT02984215
aCGH Impacts Survival in Plasma Cell PTLDNo drug interventionsNot AvailableNot Availablecompleted
NCT06666153
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative DiseasesNo drug interventionstreatment1not_yet_recruiting
NCT02182986
Biomarkers for Post-Transplant Lymphoproliferative Disorders in ChildrenNo drug interventionsNot AvailableNot Availablecompleted